This post was originally published on this site
The medical device maker and its rivals, Quest Diagnostics (NYSE:DGX) and Becton Dickinson (NYSE:BDX) and Co, banked on soaring sales of COVID-19 tests last year to cushion a lockdown-driven hit to their mainstay businesses.
But with curbs lifted and vaccinations gathering pace, demand for medical devices is returning as more people opt for non-urgent procedures.
Second-quarter sales in Abbott’s diagnostics business grew nearly 63% to $3.25 billion, with COVID-19 testing-related sales at $1.3 billion, down from the previous quarter.
The company recorded sales growth of more than 11%, excluding COVID testing, on an organic basis in the quarter compared to pre-pandemic levels.
It maintained its 2021 adjusted earnings forecast of $4.30 to $4.50 per share from continuing operations.
The company’s net earnings rose to $1.19 billion, or 66 cents per share, in the quarter ended June 30, from $537 million, or 30 cents per share, a year earlier.
